Celularity Inc
NASDAQ:CELU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Celularity Inc
Current Portion of Long-Term Debt
Celularity Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Celularity Inc
NASDAQ:CELU
|
Current Portion of Long-Term Debt
$5.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Current Portion of Long-Term Debt
$6.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Current Portion of Long-Term Debt
$2.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Current Portion of Long-Term Debt
$4.6B
|
CAGR 3-Years
42%
|
CAGR 5-Years
119%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Current Portion of Long-Term Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Celularity Inc
Glance View
Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company is headquartered in New York City, New York and currently employs 225 full-time employees. The company went IPO on 2019-05-23. The company operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), unmodified and genetically modified natural killer (NK) cells, mesenchymal-like adherent stromal cells (ASCs), and targeting therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CyCART-19 is a placental-derived CAR-T cell therapy and targeting the CD19 receptor; CYNK-001 is for the treatment of acute myeloid leukemia (AML); CYNK-101 is genetically modified version of a placental-derived NK-cell; APPL-001 developed for the treatment of Crohn’s disease, a degenerative disease, and PDA-002 developed for the treatment of Facioscapulohumeral muscular dystrophy (FSHD).
See Also
What is Celularity Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
5.7m
USD
Based on the financial report for Sep 30, 2025, Celularity Inc's Current Portion of Long-Term Debt amounts to 5.7m USD.
